BRYXTA 400MG INJ contains Bevacizumab, a monoclonal antibody used in the treatment of various cancers, including colorectal, lung, ovarian, and renal cell carcinoma. It works by inhibiting the growth of blood vessels that supply tumors, thereby slowing cancer progression. Manufactured by ZYDUS, this high-quality injection is supplied by Apple Pharmex and distributed by Quid Connect, ensuring reliability and efficacy in oncology care.
✅ Therapeutic Use: Chemotherapy adjunct for multiple cancers
✅ Dosage: 400mg per vial (as prescribed by an oncologist)
✅ Manufacturer: Zydus
✅ Supplied By: Apple Pharmex
✅ Distributed By: Quid Connect
BRYXTA 400MG INJECTION (BEVACIZUMAB) – ZYDUS | ONCOLOGY CANCER TREATMENT
₹59,995.00 Regular Price
₹26,997.75Sale Price
+%E2%80%93+ZYDUS+%7C+ONCOLOGY+CANCER+TREATMENT){kind=link}